Asset Details
Do you wish to reserve the book?
Utility of the China-PAR Score in predicting secondary events among patients undergoing percutaneous coronary intervention
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Utility of the China-PAR Score in predicting secondary events among patients undergoing percutaneous coronary intervention
Do you wish to request the book?
Utility of the China-PAR Score in predicting secondary events among patients undergoing percutaneous coronary intervention
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Utility of the China-PAR Score in predicting secondary events among patients undergoing percutaneous coronary intervention
2025
Overview
[...]there is a high demand for secondary prevention strategies to reduce adverse outcomes of CAD. According to the revised China-PAR score, there were 2259 (24.1%), 2929 (31.3%), 3143 (33.6%), and 1030 (11.0%) patients with low, moderate, high, and very high scores, respectively. To some extent, it could also predict MACCEs with a C-index of 0.588 (95% CI: 0.571–0.606), which was slightly higher than those of the GRACE (0.572, 95% CI: 0.553–0.590) and PARIS scores (0.570, 95% CI: 0.552–0.587). [...]it could potentially discriminate all MACCE subtypes except myocardial infarction [Supplementary Table 4, http://links.lww.com/CM9/C296]. [...]an updated China-PAR score is required for more precise secondary prevention by including intensive pharmacotherapy. The clinical implications of the China-PAR score are highlighted by the lack of a published decision support tool to guide self-assessment in patients with CAD. [...]it could be used to direct secondary preventative measures by clinicians, understand their risk, and enhance the adherence to the therapeutic decisions of physicians, especially in resource-constrained settings.
Publisher
Lippincott Williams & Wilkins,Lippincott Williams & Wilkins Ovid Technologies,Department of Epidemiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China%Key Laboratory of Cardiovascular Epidemiology, Chinese Academy of Medical Sciences, Beijing 100037, China%Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100037, China%National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China,Wolters Kluwer
